The most promising cancer entities to benefit from inhibiting CDK9, or its up-stream regulators or its down-stream targets would probably be those of leukemic origin as they have clearly defined genetic re-arrangements (like MLL-r) [184] or oncogenic dependence (like MYC) [185,186], allowing these cells to be targeted more specifically. The gene discussed is KMT2A; the disease is cancer.